Chongqing Holley

Chongqing Holley Pharmaceutical is a prominent Chinese pharmaceutical enterprise and a subsidiary of the Holley Group, recognized globally for its leadership in the artemisinin industry. The company specializes in the extraction, semi-synthesis, and formulation of anti-malarial treatments, maintaining a comprehensive supply chain from Artemisia annua cultivation to finished drug products. Their portfolio includes key therapies such as Artemether, Artesunate, and Dihydroartemisinin, which are critical in the global fight against malaria. Beyond infectious diseases, the company manufactures various active pharmaceutical ingredients (APIs) and generic medications. Chongqing Holley is a significant supplier to international health organizations and maintains a strong commercial presence in Africa and Southeast Asia. The company operates state-of-the-art GMP-certified manufacturing facilities and continues to invest in the optimization of artemisinin production technologies.